(Q37661443)

21 August 2017

1 reference

title

Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases (English)

1 reference

21 August 2017

Steven A Yarows

1

1 reference

21 August 2017

language of work or name

1 reference

1 January 2010

1 reference

Expert Review of Cardiovascular Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

19-33

1 reference

The renin-angiotensin-aldosterone system: a specific target for hypertension management

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Aliskiren: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Issues in blood pressure control and the potential role of single-pill combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Fixed-dose combinations improve medication compliance: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Valsartan and the kidney: review of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Clinical pharmacokinetics and pharmacodynamics of aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Study of the genetic variability of ZAC1 (PLAGL1) in French population-based samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Renin and prorenin activate pathways implicated in organ damage in human mesangial cells independent of angiotensin II production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Linear relationship between systolic and diastolic blood pressure monitored over 24 h: assessment and correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Clinical practice. Isolated systolic hypertension in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Association of suboptimal blood pressure control with body size and metabolic abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Managing cardiovascular and renal risk: the potential of direct renin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Prognostic significance of left ventricular mass change during treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arte

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.143

21 January 2018

Identifiers

DOI

10.1586/ERC.09.143

1 reference

21 August 2017

1 reference